PRINCETON, N.J. / Mar 26, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today unveiled a $1.8 million initiative to advance health equity by addressing social determinants of health (SDoH) in four countries with underserved patient needs, including Brazil, India, Thailand, and the United Kingdom. The new health equity grants are an extension of the company’s broader long-term commitment to invest $150M in health equity by 2025.
Inequities in healthcare systems present a unique global challenge, with some studies suggesting that SDoH factors account for up to 50% of health outcomes within the United States.1 The World Health Organization (WHO) defines SDoH as non-medical factors that influence health outcomes, such as: income and social status, education, physical environment, social support networks, genetics, health services and gender. As echoed by the United Nations Sustainable Development Goal #3 (Good Health & Well-being), SDoH are crucial to ensure healthy lives and promote well-being for all at all ages.2
"We know that a healthier world is attainable, but access remains a significant challenge for many patients and social determinants of health present barriers to people attaining their full potential for health and well-being,” said Cari Gallman, Executive Vice President, Corporate Affairs, Bristol Myers Squibb. “These new health equity grants reinforce Bristol Myers Squibb's commitment to ensuring all patients have access to high-quality health care, regardless of where they live.”
These healthcare-strengthening grants will support eight organizations that are addressing the root causes of inequities in an effort to deliver long-lasting impacts at a community level. The grantees were selected in countries with underserved communities living with cancer and blood disorders. Based on the outcomes of this pilot program, the Company will consider expansion to other geographies and communities to remove systemic barriers to care, and enable better access and health outcomes. The grantees include:
Bristol Myers Squibb’s Approach to Health Equity
At Bristol Myers Squibb, health equity is the opportunity for all people and communities across the globe to attain their full potential for health and well-being. Our work extends beyond traditional healthcare boundaries, emphasizing the importance of community voices and cross-sector partnerships in co-creating solutions that drive meaningful and equitable health outcomes worldwide.
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, please visit BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.
1 Hood CM, Gennuso KP, Swain GR, et al. County Health Rankings: Relationships Between Determinant Factors and Health Outcomes. American Journal of Preventive Medicine. February 2016; 50(2):129-135. doi:10.1016/j.amepre.2015.08.024
2 United Nations Department of Economic and Social Affairs – Sustainable Development. The 17 Goals. Available at https://sdgs.un.org/goals. Accessed March 2024.
Last Trade: | US$56.22 |
Daily Change: | -2.28 -3.90 |
Daily Volume: | 18,744,166 |
Market Cap: | US$114.130B |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB